Potent 2420-Class of Protease Inhibitors for Treatment of COVID-19
A new class of drug compounds potently inhibits the SARS-CoV-2 3CL-pro enzyme, effectively blocking viral replication for use in COVID-19 treatment and drug discovery.
Purdue University researchers have developed a series of compounds for the treatment of COVID-19, the respiratory illness caused by the SARS-CoV-2 coronavirus strain. While a few COVID-19 treatments have been approved for emergency use, such treatments are limited to patients with mild to moderate COVID-19 symptoms or disease recurrence occur after completing the treatment course. The Purdue compounds potently inhibit the SARS-CoV-2 3C-like protease (3CL-pro) and block SARS-CoV-2 replication in vitro. The researchers expect these compounds and their derivatives to possess drug-like properties.
Advantages:
-Potent inhibitor of SARS-CoV-2 3CL-pro enzyme
-Blocks SARS-CoV-2 viral replication
Applications:
-COVID-19 treatment
-Drug discovery
TRL: 2
Intellectual Property:
Provisional-Gov. Funding, 2022-02-07, United States | PCT-Gov. Funding, 2022-12-07, WO | CIP-Gov. Funding, 2024-08-06, United States
Keywords: COVID-19 treatment, SARS-CoV-2 inhibitor, 3CL-pro, viral replication blocker, protease inhibitor, drug discovery, antiviral compounds, respiratory illness treatment, drug-like properties, emergency use treatment